Entera Bio Ltd.

NasdaqCM ENTX

Entera Bio Ltd. EBITDA for the year ending December 31, 2023: USD -8.80 M

Entera Bio Ltd. EBITDA is USD -8.80 M for the year ending December 31, 2023, a 31.59% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Entera Bio Ltd. EBITDA for the year ending December 31, 2022 was USD -12.87 M, a -5.80% change year over year.
Entera Bio Ltd. EBITDA for the year ending December 31, 2021 was USD -12.16 M, a -9.54% change year over year.
Entera Bio Ltd. EBITDA for the year ending December 31, 2020 was USD -11.11 M, a 2.12% change year over year.
Entera Bio Ltd. EBITDA for the year ending December 31, 2019 was USD -11.35 M, a -4.99% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: ENTX

Entera Bio Ltd.

CEO	Ms. Miranda J. Toledano M.B.A.
IPO Date	June 28, 2018
Location	Israel
Headquarters	Kiryat Hadassah Minrav Building
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Key trends

Past 5 years